Molecular Response (MRL) Expands Clinical Offerings with BRAF Mutation Testing
SAN DIEGO--(BUSINESS WIRE)--Molecular Response announced today that it has launched a clinically validated BRAF test to detect the V600E mutation in both melanoma and colorectal tumors.